The Shifting Landscape of Pharmaceutical M&A in India
India’s pharmaceutical sector is a hub for mergers and acquisitions (M&A). Companies aim not only to grow but also to enhance research and development, secure new drug formulations, and enter emerging markets. The legal and regulatory landscape is constantly evolving. Ignoring it can jeopardise a deal. This guide covers the key legal considerations and developments up to September 2025. It also highlights the role of expert advisors like Law Firm, a leading corporate law firm in Mumbai, in navigating these complexities.
Recent Legal Updates Affecting Pharmaceutical M&A
Staying current with legal amendments is essential for anyone involved in M&A in India. Key developments include:
- Schedule M and WHO GMP Compliance
The CDSCO now requires manufacturers to comply with the revised Schedule M and WHO Good Manufacturing Practices (GMP). Small and medium manufacturers with a turnover under INR 250 crores have until 31 December 2025 to meet the standards. During due diligence, verify both current compliance and plans to meet the new deadline. Upgrade costs and timelines can directly affect deal valuation.
- Compounding of Offences
The Jan Vishwas (Amendment of Provisions) Act, 2023 eases penalties for minor drug regulation violations. M&A advisors can now classify some past non-compliances as “compoundable,” reducing risk exposure. Serious offences such as mislabelling or safety fraud remain non-compoundable.
- Clinical Trials and NDCT Rules
The New Drugs and Clinical Trials Rules, 2019 allow waivers for local trials of “breakthrough” drugs already approved in key markets like the USA and EU. Additionally, Chapter VA now regulates Clinical Research Organisations (CROs), which must register and comply with inspections. Due diligence should include verifying the target company’s CRO compliance.
- Drug Pricing and NPPA Scrutiny
The National Pharmaceutical Pricing Authority (NPPA) enforces the Drug Price Control Order (DPCO), 2013, with over 928 scheduled formulations capped as of March 2025. Assess the target’s history of pricing compliance and potential adjustments that may affect profitability.
Core Legal Considerations in a Pharmaceutical M&A Deal
Several legal areas remain critical to any pharmaceutical M&A transaction:
- Regulatory Approvals
Deals cannot close without approvals from:
- DCGI / CDSCO for drug-related matters
- Competition Commission of India (CCI) for antitrust review
The Competition Act amendment (2023) set a new deal value threshold of INR 2,000 crores, effective September 2024. High-value or technology-driven deals now require CCI approval.
IP often drives deal value. Conduct thorough due diligence:
- Assess patent validity
- Check ongoing litigation
- Verify data exclusivity
The Delhi High Court’s Novo Nordisk v. Dr. Reddy’s (May 2025) case shows how courts balance patent protection with India’s generic drug exports.
- Comprehensive Due Diligence
Examine financial records, contracts, and pending litigation. Include:
- Marketing compliance: Check adherence to the Uniform Code for Pharmaceutical Marketing Practices (2024)
- Supply chain and distribution: Audit against the CDSCO’s draft Good Distribution Practices (GDP)
- Foreign Direct Investment (FDI) Rules
For foreign investors:
- 100% FDI is allowed in greenfield projects (automatic route)
- Brownfield projects are capped at 74%; anything above requires DPIIT approval
Overcoming Challenges in Pharmaceutical M&A: Expert Solutions
- Regulatory Delays
Approvals from DCGI or CCI can delay deals. Legal experts like Law Firm can:
- Liaise with regulators
- Ensure filings are complete
- Use the CCI ‘Green Channel’ for faster non-competitive approvals
- Pricing & Compliance Risks
Non-compliance with NPPA can lead to fines. Advisors help:
- Audit the target’s pricing history
- Draft sale agreements to protect from future liabilities
- Integration Issues
Post-merger integration often involves:
- Consolidating manufacturing operations
- Realigning R&D teams
- Harmonising corporate cultures
Experts familiar with Indian labour laws in pharma hubs like Gujarat and Hyderabad can ensure a smooth transition.
FAQs
Q1: What regulatory approvals are required?
A: CCI for competition, DCGI/CDSCO for drug and manufacturing compliance, NPPA for pricing, and DPIIT for foreign investments.
Q2: Has FDI policy changed in 2025?
A: Greenfield projects allow 100% FDI automatically. Brownfield projects remain capped at 74%; higher investments need approval.
Q3: Which recent case laws affect M&A due diligence?
A: Supreme Court rulings on insolvency emphasise IP protection during distressed asset sales. The Novo Nordisk v. Dr. Reddy’s case illustrates the balance between IP rights and generic exports.
Q4: How do Schedule M / WHO GMP changes impact valuation?
A: Compliance upgrades are costly and time-consuming. Deal valuations should factor in capital expenditure and timelines.
Q5: What trends drive pharmaceutical M&A in India?
A: Focus on biologics, biosimilars, and generics. Companies are acquiring smaller firms for innovation and pipeline expansion.
Conclusion: Your Partner in Pharmaceutical M&A
Pharmaceutical M&A in India offers huge opportunities but involves complex legal and regulatory challenges. From Schedule M compliance and CCI scrutiny to evolving IP jurisprudence and NPPA regulations, every step demands a strategic legal approach. Partnering with experienced advisors ensures you can confidently navigate deals, mitigate risks, and achieve strategic objectives in this dynamic sector.
About LawCrust Legal Consultation.
LawCrust Legal Consulting, a subsidiary of LawCrust Global Consulting Ltd., is a trusted legal partner for NRIs and Indians across the globe. Backed by a team of over 70 expert lawyers and more than 25 empanelled law firms, we offer a wide range of Premium Legal Services both in India and internationally. Our expertise spans across legal finance, litigation management, matrimonial disputes, property matters, estate planning, heirship certificates, RERA, and builder-related legal issues.
In addition to personal legal matters, LawCrust also provides expert support in complex corporate areas such as foreign direct investment (FDI), foreign institutional investment (FII), mergers & acquisitions, and fundraising. We also assist clients with OCI and immigration matters, startup solutions, and hybrid consulting solutions. Consistently ranked among the top legal consulting firms in India, LawCrust proudly delivers customised legal solutions across the UK, USA, Canada, Europe, Australia, APAC, and EMEA, offering culturally informed and cross-border expertise to meet the unique needs of the global Indian community.